The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
A minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Imatinib Mesylate — A New Oral Targeted Therapy
Savage, D. G., & Antman, K. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmra013339 · Cited by 844
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Clinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 643
Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 643
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 612
Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
Mahon, F.-X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J. M., & Melo, J. V. (2003) · Blood · doi:10.1182/blood.v101.6.2368 · Cited by 538
Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 511
Shah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 472
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Chronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 457
Burger, H., van Tol, H., Boersma, A. W. M., Brok, M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2004) · Blood · doi:10.1182/blood-2004-04-1398 · Cited by 417
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046888 · Cited by 416
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M. B., Shan, J., Letvak, L., Thomas, D., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3800 · Cited by 392
Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Robak, T., Khoroshko, N., Masszi, T., Skotnicki, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-056028 · Cited by 377
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 374
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., & Freedman, S. J. (2007) · Blood · doi:10.1182/blood-2006-05-025049 · Cited by 364
Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 352
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
White, D. L., Saunders, V. A., Dang, P., Engler, J., Venables, A., Zrim, S., Zannettino, A., Lynch, K., Manley, P. W., & Hughes, T. (2007) · Blood · doi:10.1182/blood-2007-06-093617 · Cited by 331
Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C. A., Steegmann, J. L., et al. (2001) · Blood · doi:10.1182/blood.v98.10.3074 · Cited by 321
Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans
Wilkinson, G. R. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353475 · Cited by 311
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
Flying under the radar: the new wave of BCR–ABL inhibitors
Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2324 · Cited by 305
Cortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1616 · Cited by 283
Darkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., & Cortes, J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-12-200612190-00008 · Cited by 256
Holtz, M. S., Slovak, M. L., Zhang, F., Sawyers, C. L., Forman, S. J., & Bhatia, R. (2002) · Blood · doi:10.1182/blood.v99.10.3792 · Cited by 253
Kimura, S., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 241
Dai, Y., Rahmani, M., Corey, S. J., Dent, P., & Grant, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402290200 · Cited by 239
Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 226
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
Gumireddy, K., Baker, S. J., Cosenza, S. C., John, P., Kang, A. D., Robell, K. A., Reddy, M. V. R., & Reddy, E. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408283102 · Cited by 220
Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 215
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R., Aggarwal, B., Shishodin, S., Albitar, M., Hayes, K., Kantarjian, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1484 · Cited by 214
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Mahon, F.-X., Hayette, S., Lagarde, V., Belloc, F., Turcq, B., Nicolini, F., Belanger, C., Manley, P. W., Leroy, C., Etienne, G., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1008 · Cited by 212
Tiwari, A. K., Sodani, K., Wang, S.-R., Kuang, Y.-H., Ashby, C. R., Chen, X., & Chen, Z.-S. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.002 · Cited by 209
Self-citationDasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Hiwase, D. K., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., Eadie, L., To, L. B., Melo, J., Kumar, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5095 · Cited by 208
Cortes, J., Kim, D.-W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J.-L., et al. (2008) · Leukemia · doi:10.1038/leu.2008.221 · Cited by 202
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Barnes, D. J., Palaiologou, D., Panousopoulou, E., Schultheis, B., Yong, A. S. M., Wong, A., Pattacini, L., Goldman, J. M., & Melo, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0076 · Cited by 200
Brendel, C., Scharenberg, C., Dohse, M., Robey, R. W., Bates, S. E., Shukla, S., Ambudkar, S. V., Wang, Y., Wennemuth, G., Burchert, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404638 · Cited by 200
Branford, S., Cross, N. C. P., Hochhaus, A., Radich, J., Saglio, G., Kaeda, J., Goldman, J., & Hughes, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404388 · Cited by 196
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Chen, Y., Agarwal, S., Shaik, N. M., Chen, C., Yang, Z., & Elmquist, W. F. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154781 · Cited by 194
A brief introduction to FOXOlogy
Burgering, B. M. T. (2008) · Oncogene · doi:10.1038/onc.2008.29 · Cited by 194
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194 · cited 3×
“The initial and subsequent 2-year follow-up results indicated that dasatinib produced a significantly greater therapeutic response than high-dose imatinib for the patients in their study [75,76].”
BackgroundKamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 191
Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., MIYAWAKI, S., & Tsubaki, K. (1995) · Blood · doi:10.1182/blood.v86.3.906.906 · Cited by 190
Cortes, J., Giles, F., O'Brien, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Faderl, S., Verstovsek, S., Ferrajoli, A., Freireich, E. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0025 · Cited by 188
Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9953 · Cited by 183
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski, D. J., Lambek, C. L., Liu, C., Strife, A., Veach, D. R., Nagar, B., Young, M. A., Schindler, T. H., Bornmann, W. G., Bertino, J. R., et al. (2002) · PubMed · Cited by 174
Kantarjian, H., Cortes, J., Kim, D.-W., Dorlhiac-Llacer, P., Pasquini, R., DiPersio, J., Müller, M. C., Radich, J. P., Khoury, H. J., Khoroshko, N., et al. (2009) · Blood · doi:10.1182/blood-2008-11-186817 · Cited by 172
Wu, J., Meng, F., Kong, L.-Y., Peng, Z., Ying, Y., Bornmann, W. G., Darnay, B. G., Lamothe, B., Sun, H., Talpaz, M., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn188 · Cited by 165
Appel, S., Boehmler, A. M., Grünebach, F., Müller, M. R., Rupf, A., Weck, M. M., Hartmann, U., Reichardt, V. L., Kanz, L., Brümmendorf, T. H., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0975 · Cited by 163
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
le Coutre, P., Kreuzer, K.-A., Pursche, S., v. Bonin, M., Leopold, T., Baskaynak, G., Dörken, B., Ehninger, G., Ottmann, O., Jenke, A., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0741-6 · Cited by 161
Manley, P. W., Cowan-Jacob, S. W., & Mestan, J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.040 · Cited by 160
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
Hughes, T., & Branford, S. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.008 · Cited by 158
Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia.
Erikson, J., Griffin, C. A., ar-Rushdi, A., Valtieri, M., Hoxie, J. A., Finan, J. B., Emanuel, B. S., Rovera, G., Nowell̀, P. C., & Croce, C. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1807 · Cited by 151
Meyn, M. A., Wilson, M. B., Abdi, F. A., Fahey, N., Schiavone, A. P., Wu, J., Hochrein, J. M., Engen, J. R., & Smithgall, T. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605902200 · Cited by 137
Press, R. D., Galderisi, C., Yang, R., Rempfer, C., Willis, S. G., Mauro, M. J., Druker, B. J., & Deininger, M. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1112 · Cited by 126
Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib
van Erp, N. P., Gelderblom, H. A. J., Karlsson, M. O., Li, J., Zhao, M., Ouwerkerk, J., Nortier, J. W. R., Guchelaar, H., Baker, S. D., & Sparreboom, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0346 · Cited by 123
Important Therapeutic Targets in Chronic Myelogenous Leukemia
Kantarjian, H. M., Giles, F. J., Quintás‐Cardama, A., & Cortes, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2147 · Cited by 121
Komatsu, N., Watanabe, T., Uchida, M., Mori, M., Kirito, K., Kikuchi, S., Liu, Q., Tauchi, T., Miyazawa, K., Endo, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211562200 · Cited by 119
Natural history and staging of chronic myelogenous leukemia
Cortes, J. E. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.03.011 · Cited by 118
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
Kantarjian, H. M., Larson, R. A., Guilhot, F., O’Brien, S. G., Mone, M. D., Rudoltz, M. S., Krahnke, T., Cortes, J. E., Druker, B. J., & for the International Randomized Study of Interferon and STI571 (IRIS) Investigators (2009) · Cancer · doi:10.1002/cncr.24066 · Cited by 114
Ferrao, P. T., Frost, M. J., Siah, S.-P., & Ashman, L. K. (2003) · Blood · doi:10.1182/blood-2003-01-0083 · Cited by 97
Shukla, S., Sauna, Z. E., & Ambudkar, S. V. (2007) · Leukemia · doi:10.1038/sj.leu.2404897 · Cited by 96
Wang, H., Cheng, F., Cuenca, A. G., Horna, P., Zheng, Z., Bhalla, K. N., & Sotomayor, E. M. (2004) · Blood · doi:10.1182/blood-2004-01-0027 · Cited by 95
Appel, S., Rupf, A., Weck, M. M., Schoor, O., Brümmendorf, T. H., Weinschenk, T., Grünebach, F., & Brossart, P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1713 · Cited by 92
Jørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. D. (2002) · Blood · doi:10.1182/blood.v99.2.713 · Cited by 85
Legros, L. (2004) · Blood · doi:10.1182/blood-2003-08-2695 · Cited by 81
Press, R. D., Willis, S. G., Laudadio, J., Mauro, M. J., & Deininger, M. W. (2009) · Blood · doi:10.1182/blood-2008-08-173674 · Cited by 78
Marín, D., Goldman, J. M., Olavarría, E., et al. (2003) · Blood · doi:10.1182/blood-2003-06-2042 · Cited by 77
Shen, T., Kuang, Y., Ashby, C. R., Yu, L., Angel, C., Zhou, Y. Q., Chen, X., Tiwari, A. K., Hopper-Borge, E. A., Ouyang, J., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007520 · Cited by 72
Self-citation3 Signal transduction pathways involved in BCR-ABL transformation
Sawyers, C. L. (1997) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(97)80004-2 · Cited by 71
Imatinib Resistance: Obstacles and Opportunities
Litzow, M. R. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-669-iroao · Cited by 68
Kvasnicka, H. M., Thiele, J., Staib, P., et al. (2004) · Blood · doi:10.1182/blood-2003-08-2734 · Cited by 61
Wang, L., Knight, K., Lucas, C., & Clark, R. E. (2006) · PubMed · Cited by 61
Galimberti, S., Cervetti, G., Guerrini, F., Testi, R., Pacini, S., Fazzi, R., Simi, P., & Petrini, M. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.01.015 · Cited by 58
Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo
Taïeb, J., Maruyama, K., Borg, C., Terme, M., & Zitvogel, L. (2004) · Blood · doi:10.1182/blood-2003-10-3475 · Cited by 54
Shah, N. P. (2007) · Hematology · doi:10.1182/asheducation-2007.1.371 · Cited by 54
Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Rudoltz, M. S., Yu, R., Collins, L. R., et al. (2008) · Blood · doi:10.1182/blood.v112.11.335.335 · Cited by 53
Imatinib resistance in multidrug-resistant K562 human leukemic cells
Assef, Y. A., Rubio, F., Coló, G. P., del Mónaco, S. M., Costas, M. A., & Kotsias, B. A. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.024 · Cited by 45
Minimal residual disease in chronic myeloid leukemia
Löwenberg, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038130 · Cited by 44
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
Hatziieremia, S., Jordanides, N. E., Holyoake, T. L., Mountford, J. C., & Jørgensen, H. G. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.02.006 · Cited by 35
le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Haque, M. A., Gallagher, N. J., Baccarani, M., Cortes, J. E., & Kantarjian, H. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.7057 · Cited by 28
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor
Niwa, T., Asaki, T., & Kimura, S. H. (2007) · Analytical Chemistry Insights · doi:10.4137/117739010700200008 · Cited by 27
Barańska, M., Lewandowski, K. C., Gniot, M., Iwoła, M., Lewandowska, M., & Komarnicki, M. A. (2008) · Journal of Applied Genetics · doi:10.1007/bf03195613 · Cited by 26
Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Gallagher, N. J., Baccarani, M., & LeCoutre, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.7029 · Cited by 21
Emerging Strategies for the Treatment of Mutant Bcr-Abl T315I Myeloid Leukemia
Mughal, T. I., & Goldman, J. M. (2007) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2007.s.006 · Cited by 16
Borthakur, G., Kantarjian, H. M., O'Brien, S. M., Jones, D., Koller, C. A., Nicaise, C., Garcia-Manero, G., Ferrajoli, A., & Cortes, J. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.7013 · Cited by 16
Stone, R. M., Kim, D. W., Kantarjian, H. M., Rousselot, P. H., Hochhaus, A., Dorlhiac‐Llacer, P. E., Milone, J. H., Matloub, Y., Lambert, A., & Shah, N. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.7007 · Cited by 13
Halpern, R., Barghout, V. E., Mody‐Patel, N., & Williams, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.6598 · Cited by 11
Cited by
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Accurate and efficient detection of gene fusions from RNA sequencing data
Uhrig, S., Ellermann, J., Walther, T., Burkhardt, P., Fröhlich, M., Hutter, B., Toprak, U. H., Neumann, O., Stenzinger, A., Scholl, C., et al. (2021) · Genome Research · doi:10.1101/gr.257246.119 · Cited by 526
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry
Hruba, L., Polishchuk, P., Das, V., Hajduch, M., & Dzubak, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112549 · Cited by 8
Metadata
- Authors
- An, X., Tiwari, A. K., Sun, Y., Ding, P.-R., Ashby, C. R., & Chen, Z.-S.
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 34
- Issue
- 10
- Pages
- 1255-1268
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2021033166
- Cited by
- 309
- References
- 136
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.